Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib for severe COVID-19 pneumonia
NCT05702788Phase 2Withdrawn
- Sponsor
- Zelgen
- Start
- Sep 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of jaktinib in COVID-19 pneumonia (3 arms), sponsored by Zelgen. Primary endpoint: The proportion of Participants who develop death or respiratory failure at 28 days. Planned start Sep 2022; status: withdrawn.
02
Drugs
jaktinib
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05702788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05702788.